Navigation Links
R-Tech Ueno Starts Early Phase II Clinical Trial for RK-023
Date:10/6/2009

s release related July 16, 2009 for more information about the Phase I clinical trial.
  • In a double-blind test, for the purpose of conducting the clinical trial in a completely objective manner, the physicians performing the trial as well as the patients participating in the trial do not know if the substance administered to each individual is the drug being tested or the placebo.
  • The placebo is a substance that does not include the drug being tested (RK-023 in this case).
  • About R-Tech Ueno, Ltd.

    R-Tech Ueno was established in September 1989 for the purpose of marketing and R&D of drugs. Under the leadership of the CEO, also a medical doctor, the company is developing new drugs on the theme "Physician-Oriented New Drug Innovation," targeting ophthalmologic and dermatologic diseases that previously had no effective therapeutic agent. The company's main product Rescula(R) eyedrop 0.12% is a therapeutic drug for glaucoma and ocular hypertension and has been marketed in Japan since 1994. R-Tech Ueno was the first in the world to take advantage of the substance "prostone" in the development of Rescula(R). Prostone was discovered in 1980 by Dr. Ryuji Ueno, the founder of the company. Rescula(R) eyedrop 0.12% that causes less topical and systemic adverse reactions demonstrates steady ocular pressure-decreasing action by twice-a-day instillation. Such excellent therapeutic effects are realized through its optic nerve protection and ocular blood flow-increasing mechanism.

        Stock Code: No.4573, Osaka Securities Exchange; Hercules
        Head Office: 1-1-7 Uchisaiwai-cho, Chiyoda-ku, Tokyo
        Representative Director & President: Yukihiko Mashima
    
    
        Contact:
        Koji Nakamura,
        Business Management Department
        R-Tech Ueno, Ltd.
        Tel: +81-3-3596-8011
        e-mail: koji.nakamura@rtueno.co.jp
        URL: '/>"/>
    SOURCE R-Tech Ueno, Ltd.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
    2. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
    3. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
    4. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
    5. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
    6. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
    7. U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
    8. Presbyterian Hospital Dallas Starts Advanced Breast-Cancer Risk-Assessment Program
    9. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
    10. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
    11. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/20/2014)... 2014  Luoxis Diagnostics, Inc., a subsidiary of ... that its academic collaborators will present several peer-reviewed ... its novel RedoxSYS Diagnostic System, a first-in-class platform ... in response to injury or illness.  A poster ... clinical marker will be presented by Christopher ...
    (Date:10/20/2014)... 2014 Valeritas, Inc., a leader in simple, ... Type 2 diabetes, announced today that it has received ... award was presented October 16 th at Cardinal,s ... . The Cardinal Health Supply ... of metrics specifically targeted at the importance of developing ...
    (Date:10/20/2014)... DIEGO , Oct. 20, 2014  AnaptysBio, ... of therapeutic antibodies, today announced the appointment of ... Officer. Dr. Londei will lead the preclinical and ... "We are pleased to welcome Dr. ... Hamza Suria , President and Chief Executive Officer ...
    Breaking Medicine Technology:Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
    ... NEW YORK, March 7, 2011 Reportlinker.com ... is available in its catalogue: ... Future Growth to be Driven by Improving ... http://www.reportlinker.com/p0409144/Aesthetic-Devices-Market-to-2017---Future-Growth-to-be-Driven-by-Improving-Treatment-Outcomes-and-Increase-in-Consumer-Confidence.html ...
    ... Therapeutics Inc. (TSX: NPC), today announced that their March ... LINK: www.retailinvestorconferences.com Click the red "register/ ... will be available 24/7 for 90 days. Investors may ... the next three weeks. About Allon ...
    Cached Medicine Technology:Reportlinker Adds Aesthetic Devices Market to 2017 - Future Growth to be Driven by Improving Treatment Outcomes and Increase in Consumer Confidence 2Reportlinker Adds Aesthetic Devices Market to 2017 - Future Growth to be Driven by Improving Treatment Outcomes and Increase in Consumer Confidence 3Allon Therapeutics' CEO Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com 2Allon Therapeutics' CEO Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com 3
    (Date:10/20/2014)... With a mere 19 days to November ... brief fundraising stop at the  Law Offices of ... a debate last night with his opponent Gov. Rick ... first seven minutes because Crist had an electric fan ... in one word: "weird." , Before touching on his ...
    (Date:10/20/2014)... New York, NY (PRWEB) October 20, 2014 ... City based non-profit organization that helps New Yorkers ... lasting, positive changes toward health, housing, recovery and ... who have transformed the local community through their ... Managing Director, Marc Shapses , has been ...
    (Date:10/20/2014)... October 20, 2014 hc1.com today ... secure cloud solution that enables healthcare organizations of ... ultimate healthcare-specific customer relationship management (“CRM”) solution. , ... unique needs of the healthcare industry, the hc1 ... providers and patients by combining healthcare CRM, HIPAA-compliant ...
    (Date:10/20/2014)... 20, 2014 My Clients Plus ( ... application. The new module enables easy administration and ... life-cycle quality care. , This application allows users such ... practice, attach a to-do item to a specific client, ... set up reoccurring reminders for follow-ups. It's designed ...
    (Date:10/20/2014)... October 20, 2014 Myoderm ... as Assistant Director of their CentralSource ... managing the innovative turnkey drug sourcing, distribution, and ... brings over 12 years of industry experience, in ... at the peak of their international success to ...
    Breaking Medicine News(10 mins):Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2
    ... Eat Right, Move More and ... Milk Their Diets, DENVER, June 5 ... fad diets -- which seem to go in and out of,fashion like shoulder ... remain overweight or obese., A new campaign crossing the country, the Campaign ...
    ... ATLANTA, June 5 Elekta, a world class ... selected to supply,multiple Elekta Synergy(R) digital linear accelerator ... next few years., The new Elekta Synergy ... Radiation Therapy (IGRT), which Mary Bird Perkins,(MBP) began ...
    ... Fever for an evening of celebration, INDIANAPOLIS, June 5 ... honored by the March of Dimes on June 7 at ... help families,with critically ill babies throughout the state and to ... For several years, Anthem has teamed up with the March ...
    ... Coalition warns patients about injections on vacation ... YORK, June 5 The Physicians Coalition,for ... worldwide of the dangers of accepting Botox(R), ... from unfamiliar physicians during,vacation, cruise or spa ...
    ... watching a small group of neurons that enable sexual maturity ... near the developing nose, to deep inside the brain. ... the zebrafish will help explain why some neurons don,t make ... sexually mature as a result. , "They can go ...
    ... University researcher Bess Dawson-Hughes, M.D., chaired the ... Foundation (NOF) Clinician,s Guide to Prevention and ... Guide incorporates the World Health Organization (WHO) ... tool expected to increase the identification of ...
    Cached Medicine News:Health News:Message to Denver Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Denver Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Message to Denver Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 4Health News:Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi-Center Radiation Therapy Systems Agreement 2Health News:Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi-Center Radiation Therapy Systems Agreement 3Health News:Anthem Blue Cross and Blue Shield Honored by March of Dimes 2Health News:Botox and Restylane Not A Destination or Spa Treatment 2Health News:Botox and Restylane Not A Destination or Spa Treatment 3Health News:Botox and Restylane Not A Destination or Spa Treatment 4Health News:Zebrafish enable scientists to study the migration of neurons that enable sexual maturity 2Health News:Zebrafish enable scientists to study the migration of neurons that enable sexual maturity 3Health News:Tufts researcher leads revision of osteoporosis guidelines 2Health News:Tufts researcher leads revision of osteoporosis guidelines 3